Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




May
04
Today In Oncology
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
CLL Linked to Increased Skin Cancer Risk and Mortality
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo